RGBP is focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials as investors look to expand portfolios.

STOCK SYMBOL: RGBP

Regen Biopharma, Inc.

ABOUT REGEN BIOPHARMA, INC.

Regen Biopharma, Inc. (OTCQB: RGBP) is a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments. This includes identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently RGBP is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). RGBP is a biotechnology company focused on stem cell and immunotherapies for specialty niche treatments.

PRODUCT PIPELINE - REGEN BIOPHARMA, INC.

RGBP has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.

HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. (HemaXellerate IS CLEARED TO PROCEED TO PHASE I/II CLINICAL TRIALS)

CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing”.

DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.

RECENT DEVELOPMENTS

· RGBP sees additional positive results on its medicinal chemistry optimization for modulating NR2F6 checkpoint for treating cancer and autoimmune diseases.

· RGBP in conjunction with its medicinal chemistry partner, ChemDiv, Inc., has identified three new series of compounds that activate NRF26.

· RGBP completed the first phase of its small molecule optimization program, which involved synthesizing more than 40 analogues of its initial lead compounds (RG-NA01, RG-NA02, RG-NI01 and RG-NI02).

· RGBP announced that its management team has agreed to collectively cancel 16,500,000 common shares and 15,000,000 Series A Preferred shares.

RECENT PRESS RELEASES

· Regen BioPharma, Inc. Addresses Potential Impact of Recent Bristol Myers Squibb's $2.3 Billion Acquisition of IFM Therapeutics. Regen BioPharma Inc. (RGBP) and (RGBPP) sees recent deal activity in the immune oncology space as an indication that big pharma continues to place significant bets on the ability of biotech companies to create the innovation they seek. https://finance.yahoo.com/news/regen-biopharma-inc-addresses-potential-110000864.html

· Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators. Regen BioPharma Inc. (RGBP) and (RGBPP) today reported continued progress in Regen's development of small molecule drugs that activate and inhibit NR2F6. https://finance.yahoo.com/news/regen-biopharma-inc-research-demonstrates-120000740.html

· Regen BioPharma, Inc. Researchers Discover New Dynamic Compound Which Modulates the NR2F6 Checkpoint. Regen BioPharma Inc. (RGBP) and (RGBPP), today reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that using a focused compound library and Regen's patented screening methodology; it has identified a dynamic new chemical compound series that modulates NR2F6. https://finance.yahoo.com/news/regen-biopharma-inc-researchers-discover-120000579.html

· Regen BioPharma, Inc. Sees Additional Positive Results on its Medicinal Chemistry Optimization for Modulating NR2F6 Checkpoint for Treating Cancer and Autoimmune Diseases. Regen BioPharma Inc. (RGBP) and (RGBPP) states that progress continues to be achieved by Regen in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that ChemDiv, Inc., Regen's medicinal chemistry partner, has currently identified three series of compounds which activate NR2F6. Regen is working towards small molecule therapies that can treat cancer as well as autoimmune disorders such as arthritis and lupus. https://finance.yahoo.com/news/regen-biopharma-inc-sees-additional-120000036.html

Regen Biopharma, Inc.

4700 Spring Street

Suite 304

La Mesa, CA 91942

David.koos@regenbiopharma.com

www.regenbiopharmainc.com

http://www.frontpagestocks.com/regen-biopharma-inc-rgbp/

http://badassstocks.com/stock-alert-regen-biopharma-rgbp/